Lupin's Famotidine for Oral Suspension receives FDA approval

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the US Food and Drug Administration (FDA) for its Famotidine for Oral Suspension (40 mg / 5 mL).  Commercial shipments of the product have already commenced.

Lupin's Famotidine for Oral Suspension is the AB-rated generic equivalent of Merck's PEPCID® indicated for the short-term treatment of active duodenal ulcer, active benign gastric ulcer, and gastroesophageal reflux disease (GERD).    PEPCID for Oral Suspension had annual sales of approximately $29 million for the twelve months ended March 2010, based on IMS Health sales data.